Palomer Xavier, Barroso Emma, Zarei Mohammad, Botteri Gaia, Vázquez-Carrera Manuel
Pharmacology Unit, Department of Pharmacology and Therapeutic Chemistry, Institut de Biomedicina de la UB (IBUB), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Institut de Recerca Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Pharmacology Unit, Department of Pharmacology and Therapeutic Chemistry, Institut de Biomedicina de la UB (IBUB), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Institut de Recerca Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Biochim Biophys Acta. 2016 Oct;1861(10):1569-78. doi: 10.1016/j.bbalip.2016.01.019. Epub 2016 Jan 26.
Cardiac lipid metabolism is the focus of attention due to its involvement in the development of cardiac disorders. Both a reduction and an increase in fatty acid utilization make the heart more prone to the development of lipotoxic cardiac dysfunction. The ligand-activated transcription factor peroxisome proliferator-activated receptor (PPAR)β/δ modulates different aspects of cardiac fatty acid metabolism, and targeting this nuclear receptor can improve heart diseases caused by altered fatty acid metabolism. In addition, PPARβ/δ regulates glucose metabolism, the cardiac levels of endogenous antioxidants, mitochondrial biogenesis, cardiomyocyte apoptosis, the insulin signaling pathway and lipid-induced myocardial inflammatory responses. As a result, PPARβ/δ ligands can improve cardiac function and ameliorate the pathological progression of cardiac hypertrophy, heart failure, cardiac oxidative damage, ischemia-reperfusion injury, lipotoxic cardiac dysfunction and lipid-induced cardiac inflammation. Most of these findings have been observed in preclinical studies and it remains to be established to what extent these intriguing observations can be translated into clinical practice. This article is part of a Special Issue entitled: Heart Lipid Metabolism edited by G.D. Lopaschuk.
心脏脂质代谢因其与心脏疾病的发生发展相关而备受关注。脂肪酸利用的减少和增加都会使心脏更容易发生脂毒性心脏功能障碍。配体激活的转录因子过氧化物酶体增殖物激活受体(PPAR)β/δ调节心脏脂肪酸代谢的不同方面,靶向这种核受体可以改善由脂肪酸代谢改变引起的心脏病。此外,PPARβ/δ调节葡萄糖代谢、内源性抗氧化剂的心脏水平、线粒体生物发生、心肌细胞凋亡、胰岛素信号通路以及脂质诱导的心肌炎症反应。因此,PPARβ/δ配体可以改善心脏功能,减轻心脏肥大、心力衰竭、心脏氧化损伤、缺血再灌注损伤、脂毒性心脏功能障碍和脂质诱导的心脏炎症的病理进展。这些发现大多在临床前研究中观察到,这些有趣的观察结果在多大程度上能够转化为临床实践仍有待确定。本文是由G.D. Lopaschuk编辑的名为《心脏脂质代谢》的特刊的一部分。